Biotech News
News | Bavarian Nordic
December 13, 2023 | Company Announcements
New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic
November 30, 2023 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
November 16, 2023 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Nine Months of 2023
October 25, 2023 | Company Announcements
Bavarian Nordic’s Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk
August 31, 2023 | Company Announcements
Bavarian Nordic Provides Update on COVID-19 Booster Vaccine Program
August 23, 2023 | Company Announcements
Bavarian Nordic Announces First Half 2023 Results
August 06, 2023 | Company Announcements
Bavarian Nordic Reports Positive Phase 3 Topline Results for Chikungunya Virus Vaccine in Adults and Adolescents
August 03, 2023 | Company Announcements
Bavarian Nordic Receives USD 120 Million Contract for the Manufacturing of Smallpox and Mpox Vaccine from the U.S. Government
July 22, 2023 | Company Announcements
Bavarian Nordic Provides Update on RSV Vaccine Program
June 27, 2023 | Company Announcements
Bavarian Nordic Reports Phase 3 Topline Results for its COVID-19 Booster Vaccine Candidate
June 23, 2023 | Company Announcements
Bavarian Nordic to Supply Smallpox Vaccines for EU Strategic Reserve
June 20, 2023 | Company Announcements
Bavarian Nordic Reports Data from a Phase 3 Clinical Trial of its VLP-Based Chikungunya Virus Vaccine in Adults ≥65 Years of Age
June 16, 2023 | Company Announcements
Bavarian Nordic Reports 12-Month Durability Data from a Phase 2 Clinical Trial of its COVID-19 Vaccine Candidate
June 12, 2023 | Company Announcements
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
May 23, 2023 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
May 17, 2023 | Company Announcements
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program
May 15, 2023 | Company Announcements
Bavarian Nordic Completes Acquisition of Travel Vaccine Portfolio from Emergent BioSolutions
May 09, 2023 | Company Announcements
Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme Obligations
May 09, 2023 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Three Months of 2023
April 11, 2023 | Company Announcements
Bavarian Nordic Completes Case Accrual for RSV Phase 3 Clinical Trial
March 30, 2023 | Company Announcements
Resolutions of the Annual General Meeting 2023 of Bavarian Nordic A/S
March 16, 2023 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
March 07, 2023 | Company Announcements
Bavarian Nordic A/S – Notice Convening Annual General Meeting
March 02, 2023 | Company Announcements
Bavarian Nordic Publishes Annual Report 2022
February 23, 2023 | Company Announcements
Bavarian Nordic A/S - Registration of Share Capital Increase of 7,046,839 New Shares Completed